3月14日 - ** 药物开发商Eton PharmaceuticalsETON.O股价盘前上涨6.2%至15.51美元
** 该公司称 (link)，其实验性药物ET-600通过了与美国食品及药物管理局批准的具有相同活性成分的参比产品的生物等效性研究，用于治疗一种名为中枢性糖尿病性血尿的罕见疾病$(CDI.NZ)$
** 生物等效性研究将仿制药试验配方与原参比药物进行比较
** 中枢性尿崩症是一种不常见的疾病，患者的身体无法正常平衡液体水平，从而产生大量尿液。
** 伊顿制药计划于2025年4月向FDA提交上市申请
** 截至上次收盘，公司股价在过去12个月中上涨了两倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.